🇺🇸 Honolulu, Hawaii, USA
Gang-Ming Zou has completed his Ph.D. in 2001 from Paris VI University in France and postdoctoral studies from University of Chicago and Johns Hopkins University School of Medicine in USA. He once served as a Scientific Review Officer (SRO) in NIH before he moved to Shanghai in 2009. He was the professor and principal investigator (PI) in Shanghai Cancer Institute, and Shanghai Institute for Pediatrics Research, Shanghai Jiao Tong University in China. He was the Chief of Section of Stem Cell Biology in the National laboratory of Oncogene and Related Genes in Shanghai Cancer Institute from 2009 to 2014. He is also a Professor in Nanchang University Hospital in China since 2015. He has been listed in “Who’s Who in the World, Marquis” Since 2010. He has published more than 30 peer-reviewed papers in reputed journals, including PNAS, Blood, Oncogene, and Stem Cells etc, His accomplishment include that he identified the relevance between Pu.1 level and early B cell development, and Redox factor Ape1 in stem cell differentiation etc. Currently, his funded research is focusing on VSEL biology and stem cell in liver regeneration; and pancreatic cancer stem cell biology. He once served as a co-chair for session of stem cell therapy for liver disease (Track 4-7) in BIT’s 3rd Annual World Congress of Regenerative Medicine & Stem Cells 2010 (Shanghai, China). In 2014, he returned to USA to found “American Journal of Translational Medicine” for publication through Hawaii Gangze Inc. a publisher located in Honolulu. Current he is a president and CEO in Hawaii Gangze Inc in Honolulu, USA and editor-in-chief for American Journal of Translational Medicine.
